Jiya Acquisition said in the filing it intends to targe the biopharmaceutical sector with proceeds from the IPO. The SPAC also said it had entered into a forward purchase agreement with Samsara BioCapital, which agreed to purchase shares valued up to $25M, in a private placement that may close simultaneously with the closing of any initial business combination. Read more.
Jiya Acquisition Corp. Registers Prelim Prospectus for $100M IPO
